Alector, Inc.

NASDAQ:ALEC

Biotechnology

Healthcare
$2.57 +5.13%

+$0.08 today

Market cap
$382.61M
Beta
0.59
P/E (TTM)
-1.4
EPS (TTM)
-$1.13
52W Low $1.09High $3.40

Volume 2.13M

Average 0.65M

ALEC Selling, General & Admin

Overhead costs of running the business, including sales, marketing, management, and administrative staff.

Alector, Inc.NASDAQ: ALEC

Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026

Selling, general & admin declines year over year

Q1 FY2026 selling, general & admin of $8.11M fell 44.9% year over year, behind the -20.9% change in trailing-twelve-month selling, general & admin. Sequentially, it fell 39.2% from the prior quarter. Over 3 fiscal years it compounded at -4.0% a year.

Context

  • Selling, general & admin amounted to 256.5% of revenue in FY2025, up 199.4 pp from a year earlier.
  • Selling, general & admin increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether selling, general & admin reaches the consensus estimate from 4 analysts of $165.69M (+206.9%) for the fiscal year ending Dec 2026, a step up from the -6.0% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$8.11M-39.2% QoQ
Last fiscal yearDec 2025
$53.99M-6.0% YoY
LTMMar 2026
$47.37M-20.9% YoY
Selling, General & Admin past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-44.9%-89.4%-44.5 pp
1 year-6.0%+206.9%+212.9 pp
3-year CAGR-4.0%-47.1%-43.1 pp
5-year CAGR-28.1%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Selling, General & Admin history

USD · from the income statement

Latest · FY2025
53.99M USD
Year-over-year change
-6.0%
4-year CAGR
-0.5%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Selling, General & Admin vs competitors

How ALEC compares with its peers on the latest reported figures

  • Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -20.9% is the 8th highest of 9, against a peer median of -4.7%.
  • Selling, general & admin amounts to 257.2% of revenue for ALEC, versus a peer median of 425.2%.
ALEC Competitors
Selling, General & Admin for ALEC and competitors
Company Period LTM YoY 3-year CAGR% of revenue
VORVor Biopharma Inc.LTM Mar 2026$51.12M USD+107.0%+36.0%—
ALECAlector, Inc.LTM Mar 2026$47.37M USD-20.9%-4.0%257.2%
FATEFate Therapeutics, Inc.LTM Mar 2026$42.34M USD-49.3%-18.0%670.4%
NKTXNkarta, Inc.LTM Mar 2026$25.06M USD-19.7%+4.0%—
PEPGPepGen Inc.LTM Mar 2026$22.56M USD+1.9%+16.6%—
IRDOpus Genetics, Inc.LTM Mar 2026$21.57M USD+8.6%+44.6%180.0%
ABOSAcumen Pharmaceuticals, Inc.LTM Mar 2026$18.46M USD-7.7%+13.7%—
MOLNMolecular Partners AGLTM Mar 2026CHF 16.11M CHF-3.8%-12.0%—
CRBPCorbus Pharmaceuticals Holdings, Inc.LTM Mar 2026$15.52M USD-5.5%-6.6%—
Peer median (excluding ALEC) —-4.7%+8.9%425.2%

Competitors are the stored peer set for ALEC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue207.09M133.62M97.06M100.56M21.05M
Cost of Revenue189.41M08.85M185.94M9.66M
Gross Profit17.68M133.62M88.21M(85.38M)11.38M
Gross Margin8.5%100.0%90.9%-84.9%54.1%
Research & Development189.41M210.42M192.12M209.24M123.07M
Selling, General & Admin55.04M61.03M56.69M57.41M53.99M
Operating Expenses55.04M271.45M239.95M59.62M157.19M
Depreciation & Amortization8.32M8.47M8.85M8.84M9.66M
EBITDA(28.01M)(121.58M)(116.33M)(110.08M)(133.1M)
EBITDA Margin-13.5%-91.0%-119.9%-109.5%-632.5%
Operating Income(37.36M)(137.83M)(151.74M)(145M)(145.81M)
Operating Margin-18.0%-103.2%-156.3%-144.2%-692.8%
Interest Income00000
Interest Expense00000
Other Income / Expenses1.03M7.78M26.56M26.08M3.05M
Income Before Tax(36.33M)(130.06M)(125.18M)(118.92M)(142.76M)
Pre-Tax Margin-17.5%-97.3%-129.0%-118.3%-678.4%
Income Tax Expense03.25M5.21M128K168K
Net Income(36.33M)(133.31M)(130.39M)(119.05M)(142.93M)
Net Margin-17.5%-99.8%-134.3%-118.4%-679.2%
EPS (Basic)(0.45)(1.62)(1.56)(1.23)(1.39)
EPS (Diluted)(0.45)(1.62)(1.56)(1.23)(1.39)
Weighted Avg Shares80.42M82.47M83.73M96.59M103M
Weighted Avg Shares (Diluted)80.42M82.47M83.73M96.59M103M

Alector, Inc.

NASDAQ:ALEC

Intrinsic Alpha fair value

Locked

Current Price

$2.57

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.